Terminologies de Santé (Publiées par l'ANS)
0.1.0 - ci-build France flag

Terminologies de Santé (Publiées par l'ANS) - Local Development build (v0.1.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

ValueSet: JDV_HL7_ObservationInterpretation_CISIS

Official URL: https://smt.esante.gouv.fr/fhir/ValueSet/2.16.840.1.113883.1.11.78 Version: 20100101000000
Active as of 2010-01-01 Responsible: Agence du Numérique en Santé(ANS) -2 - 10 Rue d'Oradour-sur-Glane, 75015 Paris Computable Name: JDV_HL7_ObservationInterpretation_CISIS
Other Identifiers: OID:2.16.840.1.113883.1.11.78

JDV_HL7_ObservationInterpretation_CISIS

References

This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)

Recherche en live sur le SMT

Indiquer un mot clé puis taper sur "enter" :
                    Requête sur le SMT
                

Logical Definition (CLD)

Generated Narrative: ValueSet 2.16.840.1.113883.1.11.78

version: 4; Last updated: 2024-12-19 05:04:07+0000

Profile: Shareable ValueSet

  • Include these codes as defined in http://terminology.hl7.org/CodeSystem/v3-ObservationInterpretation
    CodeDisplayDefinition
    <Inférieur à la limite de détectionThe result is below the minimum detection limit (the test procedure or equipment is the limiting factor).

    Synonyms: Below analytical limit, low off scale.
    >Supérieur à la limite maximale de mesureThe result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor).

    Synonyms: Above analytical limit, high off scale.
    AAnormalThe result or observation value is outside the reference range or expected norm (as defined for the respective test procedure).

    \[Note: Typically applies to non-numeric results.\]
    AATrès anormal, alerteThe result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure).

    \[Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.\]
    BAméliorationThe current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure).

    \[Note: This can be applied to quantitative or qualitative observations.\]
    CARPorteur d'une forme altérée d'un gèneThe patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.
    DDiminution significative par rapport au résultat antérieurThe current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure).
    DETDétectéThe measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure.
    EÉquivoqueThe test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria.
    EXHors seuilsThe observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.

    **Example:** A positive result on a Hepatitis screening test.

    *Open Issue:* EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C\_VOCAB\_RCRIM\_l\_quade\_RCRIM Obs Interp\_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x\_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held.
    EXPAttenduThis result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Expected" (e.g., presence of drugs in a patient that is taking prescription medication for pain management).
    HAnormalement hautThe result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure).

    Synonym: Above high normal
    HHTrès anormalement haut, alerteThe result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).

    Synonym: Above upper panic limits.
    HUSignificativement hautA test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.
    HXHors seuil supérieurThe observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.

    **Example:** A positive result on a Hepatitis screening test.

    *Open Issue:* EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C\_VOCAB\_RCRIM\_l\_quade\_RCRIM Obs Interp\_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x\_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held.
    IIntermédiaireBacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized\_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2

    \[Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.\]

    \[Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.\]

    \[Note 3: This class also indicates a "buffer zone," to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.\]

    \[Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).\]
    IEPreuves insuffisantesThere is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible.

    \[Note: A MIC with "IE" and/or a comment may be reported (without an accompanying S, I or R-categorization).\]
    INDIndéterminéThe specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure.

    *Usage Note:* For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then "indeterminate" (i.e. "cannot be determined") is the appropriate response, not "equivocal".
    LAnormalement basThe result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure).

    Synonym: Below low normal
    LLTrès anormalement bas, alerteThe result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).

    Synonym: Below lower panic limits.
    LUSignificativement basA test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.
    LXHors seuil inférieurThe numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported.

    **Example:** A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3

    *Open Issue:* EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C\_VOCAB\_RCRIM\_l\_quade\_RCRIM Obs Interp\_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x\_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held.
    NNormalThe result or observation value is within the reference range or expected norm (as defined for the respective test procedure).

    \[Note: Applies to numeric or non-numeric results.\]
    NCLPas de standard définiUse when not enough clinical trial data published by the Clinical and Laboratory Standards Institutes (CLSI) is available to establish the breakpoints for susceptible / intermediate and resistant.
    NDNon détectéThe presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure.
    NEGNégatifAn absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.

    \[Note: Negative does not necessarily imply the complete absence of the specified item.\]
    NRNon réactifAn absence finding used to indicate that the specified component / analyte did not react measurably with the reagent.
    NSNon sensibleA category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible.

    NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set.

    NOTE 2: For strains yielding results in the "nonsusceptible" category, organism identification and antimicrobial susceptibility test results should be confirmed.

    Synonym: decreased susceptibility.
    POSPositifA presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.
    RRésistantBacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized\_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2

    \[Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.\]

    \[Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).\]
    RRRéactifA presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test.
    SSensibleBacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized\_Terminolo.htm) Synonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2

    \[Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.\]

    \[Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).\]
    SDDSensible à forte doseA category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates.

    Reference: CLSI document M44-A2 2009 "Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition" - page 2.
    SYN-RSynergie - résistantA category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective.

    *Usage Note:* Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.

    *Open Issue:* The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found.
    SYN-SSynergie - sensibleA category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective.

    *Usage Note:* Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.

    *Open Issue:* The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found.
    UAugmentation significative par rapport au résultat antérieurThe current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure).
    UNEInattenduThis result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Unexpected" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management).
    WDégradationThe current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure).

    \[Note: This can be applied to quantitative or qualitative observations.\]
    WRFaiblement réactifA weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test.

 

Expansion

Generated Narrative: ValueSet

version: 4; Last updated: 2024-12-19 05:04:07+0000

Profile: Shareable ValueSet

Expansion done internally based on codesystem ObservationInterpretation v3.0.0 (CodeSystem)

This value set contains 39 concepts

CodeSystemDisplayDefinition
  <http://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationInférieur à la limite de détection

The result is below the minimum detection limit (the test procedure or equipment is the limiting factor).

Synonyms: Below analytical limit, low off scale.

  >http://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationSupérieur à la limite maximale de mesure

The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor).

Synonyms: Above analytical limit, high off scale.

  Ahttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationAnormal

The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure).

[Note: Typically applies to non-numeric results.]

  AAhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationTrès anormal, alerte

The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure).

[Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.]

  Bhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationAmélioration

The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure).

[Note: This can be applied to quantitative or qualitative observations.]

  CARhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationPorteur d'une forme altérée d'un gène

The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.

  Dhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationDiminution significative par rapport au résultat antérieur

The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure).

  DEThttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationDétecté

The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure.

  Ehttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationÉquivoque

The test or procedure was successfully performed, but the results are borderline and can neither be declared positive / negative nor detected / not detected according to the current established criteria.

  EXhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationHors seuils

The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.

Example: A positive result on a Hepatitis screening test.

Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held.

  EXPhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationAttendu

This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Expected" (e.g., presence of drugs in a patient that is taking prescription medication for pain management).

  Hhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationAnormalement haut

The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure).

Synonym: Above high normal

  HHhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationTrès anormalement haut, alerte

The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).

Synonym: Above upper panic limits.

  HUhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationSignificativement haut

A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.

  HXhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationHors seuil supérieur

The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.

Example: A positive result on a Hepatitis screening test.

Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held.

  Ihttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationIntermédiaire

Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2

[Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.]

[Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.]

[Note 3: This class also indicates a "buffer zone," to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.]

[Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]

  IEhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationPreuves insuffisantes

There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible.

[Note: A MIC with "IE" and/or a comment may be reported (without an accompanying S, I or R-categorization).]

  INDhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationIndéterminé

The specified component / analyte, organism or clinical sign could neither be declared positive / negative nor detected / not detected by the performed test or procedure.

Usage Note: For example, if the specimen was degraded, poorly processed, or was missing the required anatomic structures, then "indeterminate" (i.e. "cannot be determined") is the appropriate response, not "equivocal".

  Lhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationAnormalement bas

The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure).

Synonym: Below low normal

  LLhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationTrès anormalement bas, alerte

The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).

Synonym: Below lower panic limits.

  LUhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationSignificativement bas

A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.

  LXhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationHors seuil inférieur

The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported.

Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3

Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g., A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held.

  Nhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationNormal

The result or observation value is within the reference range or expected norm (as defined for the respective test procedure).

[Note: Applies to numeric or non-numeric results.]

  NCLhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationPas de standard défini

Use when not enough clinical trial data published by the Clinical and Laboratory Standards Institutes (CLSI) is available to establish the breakpoints for susceptible / intermediate and resistant.

  NDhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationNon détecté

The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure.

  NEGhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationNégatif

An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.

[Note: Negative does not necessarily imply the complete absence of the specified item.]

  NRhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationNon réactif

An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent.

  NShttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationNon sensible

A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible.

NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set.

NOTE 2: For strains yielding results in the "nonsusceptible" category, organism identification and antimicrobial susceptibility test results should be confirmed.

Synonym: decreased susceptibility.

  POShttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationPositif

A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.

  Rhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationRésistant

Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2

[Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.]

[Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]

  RRhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationRéactif

A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test.

  Shttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationSensible

Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) Synonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2

[Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.]

[Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms).]

  SDDhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationSensible à forte dose

A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates.

Reference: CLSI document M44-A2 2009 "Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition" - page 2.

  SYN-Rhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationSynergie - résistant

A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective.

Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.

Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found.

  SYN-Shttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationSynergie - sensible

A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective.

Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.

Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found.

  Uhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationAugmentation significative par rapport au résultat antérieur

The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure).

  UNEhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationInattendu

This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Unexpected" (e.g., presence of non-prescribed drugs in a patient that is taking prescription medication for pain management).

  Whttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationDégradation

The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure).

[Note: This can be applied to quantitative or qualitative observations.]

  WRhttp://terminology.hl7.org/CodeSystem/v3-ObservationInterpretationFaiblement réactif

A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test.


Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code